In a report issued on June 30, Joshua Schimmer from Evercore ISI maintained a Buy rating on Talaris Therapeutics (TALS – Research Report), with a price target of $11.00. The company's shares closed last Friday at $2.30, close to its 52-week low of $2.04. According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 3.4% and a 47.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, BioMarin Pharmaceutical, and Aeglea Biotherapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Talaris Therapeutics with a $12.67 average price target.
https://www.tipranks.com/news/blurbs/evercore-isi-thinks-talaris-therapeutics-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral